Eye on Pharma: Eylea Biosimilar Suspension; New FDA Labeling Guidance; Alvotech Reinspection

Samsung Bioepis suspends development for its biosimilar referencing Eylea (aflibercept); the FDA updates its labeling recommendations for interchangeable biosimilars; Alvotech receives a Form 483 after the FDA reinspected its Iceland-based manufacturing facility.

Related Keywords

Iceland ,Reykjavik ,C10 ,South Korea ,Korea ,Samsung Bioepi Eylea ,Samsung Bioepi ,Stantond Alvotech ,Sarah Yim ,Samsung Bioepis ,Samsung Bioepis Suspends Aflibercept Development ,Bioprocess International ,Korean Ministry Of Food ,Korean Ministry ,Drug Safety ,Korea Biomedical ,Pharmaceutical Affairs ,Biosimilarity Statement ,New Drug Office ,Therapeutic Biologics ,Reinspection Results ,Cosmetic Act ,Alvotech ,Eylea ,Aflibercept ,Usfda Inspection ,Fda Labeling ,Fda Guidance ,Avt04 ,Avt06 ,Form 483 ,